S
SELECT Trial
Study / ResearchMentioned in 1 video
A significant study, sponsored by Nova Nordisk, that showed a 20% reduction in severe cardiovascular events in overweight individuals (without Type 2 diabetes) on Semaglutide, independent of weight loss.
